|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Karlsson MC, Gonzalez SF, Welin J and Fuxe
J: Epithelial-mesenchymal transition in cancer metastasis through
the lymphatic system. Mol Oncol. 11:781–791. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Poncy A, Antoniou A, Cordi S, Pierreux CE,
Jacquemin P and Lemaigre FP: Transcription factors SOX4 and SOX9
cooperatively control development of bile ducts. Dev Biol.
404:136–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jang SM, Kim JW, Kim CH, An JH, Johnson A,
Song PI, Rhee S and Choi KH: KAT5-mediated SOX4 acetylation
orchestrates chromatin remodeling during myoblast differentiation.
Cell Death Dis. 6:e18572015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tiwari N, Tiwari VK, Waldmeier L, Balwierz
PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schübeler D, van
Nimwegen E and Christofori G: Sox4 is a master regulator of
epithelial-mesenchymal transition by controlling Ezh2 expression
and epigenetic reprogramming. Cancer Cell. 23:768–783. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang B, Li Y, Tan F and Xiao Z: Increased
expression of SOX4 is associated with colorectal cancer
progression. Tumour Biol. 37:9131–9137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bilir B, Osunkoya AO, Wiles WG IV,
Sannigrahi S, Lefebvre V, Metzger D, Spyropoulos DD, Martin WD and
Moreno CS: SOX4 is essential for prostate tumorigenesis initiated
by PTEN ablation. Cancer Res. 76:1112–1121. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hasegawa S, Nagano H, Konno M, Eguchi H,
Tomokuni A, Tomimaru Y, Asaoka T, Wada H, Hama N, Kawamoto K, et
al: A crucial epithelial to mesenchymal transition regulator,
Sox4/Ezh2 axis is closely related to the clinical outcome in
pancreatic cancer patients. Int J Oncol. 48:145–152. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sung WJ, Kim H and Park KK: The biological
role of epithelial-mesenchymal transition in lung cancer (Review).
Oncol Rep. 36:1199–1206. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao
X, Feng J, Zhang Y, Gao H, Liu DX, et al: SOX4 induces
epithelial-mesenchymal transition and contributes to breast cancer
progression. Cancer Res. 72:4597–4608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sinner D, Kordich JJ, Spence JR, Opoka R,
Rankin S, Lin SC, Jonatan D, Zorn AM and Wells JM: Sox17 and Sox4
differentially regulate beta-catenin/T-cell factor activity and
proliferation of colon carcinoma cells. Mol Cell Biol.
27:7802–7815. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiao C, Song Z, Chen J, Zhong J, Cai W,
Tian S, Chen S, Yi Y and Xiao Y: lncRNA-UCA1 enhances cell
proliferation through functioning as a ceRNA of Sox4 in esophageal
cancer. Oncol Rep. 36:2960–2966. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang W, Zhang E and Lin C: MicroRNAs in
tumor angiogenesis. Life Sci. 136:28–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang J, Zhang SY, Gao YM, Liu YF, Liu YB,
Zhao ZG and Yang K: MicroRNAs as oncogenes or tumour suppressors in
oesophageal cancer: Potential biomarkers and therapeutic targets.
Cell Prolif. 47:277–286. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim VN, Han J and Siomi MC: Biogenesis of
small RNAs in animals. Nat Rev Mol Cell Biol. 10:126–139. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thomson DW, Bracken CP and Goodall GJ:
Experimental strategies for microRNA target identification. Nucleic
Acids Res. 39:6845–6853. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rupaimoole R, Calin GA, Lopez-Berestein G
and Sood AK: miRNA deregulation in cancer cells and the tumor
microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Magee P, Shi L and Garofalo M: Role of
microRNAs in chemoresistance. Ann Transl Med. 3:3322015.PubMed/NCBI
|
|
19
|
Yin K, Yin W, Wang Y, Zhou L, Liu Y, Yang
G, Wang J and Lu J: MiR-206 suppresses epithelial mesenchymal
transition by targeting TGF-β signaling in estrogen receptor
positive breast cancer cells. Oncotarget. 7:24537–24548. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu Y, Zhao Y, Sun XH, Ge J, Zhang B, Wang
X and Cao XC: Down-regulation of miR-129-5p via the Twist1-Snail
feedback loop stimulates the epithelial-mesenchymal transition and
is associated with poor prognosis in breast cancer. Oncotarget.
6:34423–34436. 2015.PubMed/NCBI
|
|
21
|
Rhodes LV, Martin EC, Segar HC, Miller DF,
Buechlein A, Rusch DB, Nephew KP, Burow ME and Collins-Burow BM:
Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the
inhibition of epithelial-to-mesenchymal transition in
triple-negative breast cancer. Oncotarget. 6:16638–16652. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang S, Li Y, Gao J, Zhang T, Li S, Luo A,
Chen H, Ding F, Wang X and Liu Z: MicroRNA-34 suppresses breast
cancer invasion and metastasis by directly targeting Fra-1.
Oncogene. 32:4294–4303. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pichler M and Calin GA: MicroRNAs in
cancer: From developmental genes in worms to their clinical
application in patients. Br J Cancer. 113:569–573. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wan LY, Deng J, Xiang XJ, Zhang L, Yu F,
Chen J, Sun Z, Feng M and Xiong JP: miR-320 enhances the
sensitivity of human colon cancer cells to chemoradiotherapy in
vitro by targeting FOXM1. Biochem Biophys Res Commun. 457:125–132.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang T, Zou P, Wang T, Xiang J, Cheng J,
Chen D and Zhou J: Down-regulation of miR-320 associated with
cancer progression and cell apoptosis via targeting Mcl-1 in
cervical cancer. Tumour Biol. 37:8931–8940. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun JY, Xiao WZ, Wang F, Wang YQ, Zhu YH,
Wu YF, Miao ZL and Lin YC: MicroRNA-320 inhibits cell proliferation
in glioma by targeting E2F1. Mol Med Rep. 12:2355–2359. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ,
Lee KH, Yeh SD, Hong TM and Chen YL: MicroRNA-320 suppresses the
stem cell-like characteristics of prostate cancer cells by
downregulating the Wnt/beta-catenin signaling pathway.
Carcinogenesis. 34:530–538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu YY, Chen YL, Jao YC, Hsieh IS, Chang KC
and Hong TM: miR-320 regulates tumor angiogenesis driven by
vascular endothelial cells in oral cancer by silencing neuropilin
1. Angiogenesis. 17:247–260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vishnubalaji R, Hamam R, Yue S, Al-Obeed
O, Kassem M, Liu FF, Aldahmash A and Alajez NM: MicroRNA-320
suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1.
Oncotarget. 7:35789–35802. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH
and van de Vijver MJ: WHO Classification of Tumours of the Breast.
4th edition. Lyon: IARC Press; 2012
|
|
31
|
Zhang YF, Yu Y, Song WZ, Zhang RM, Jin S,
Bai JW, Kang HB, Wang X and Cao XC: miR-410-3p suppresses breast
cancer progression by targeting Snail. Oncol Rep. 36:480–486. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The microRNA.org resource: Targets and expression.
Nucleic Acids Res. 36:(Database Issue). D149–D153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Adlakha YK and Saini N: MicroRNA: A
connecting road between apoptosis and cholesterol metabolism.
Tumour Biol. 37:8529–8554. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen Y, Yang X, Xu Y, Cao J and Chen L:
Genomic analysis of drug resistant small cell lung cancer cell
lines by combining mRNA and miRNA expression profiling. Oncol Lett.
13:4077–4084. 2017.PubMed/NCBI
|
|
35
|
Macedo T, Silva-Oliveira RJ, Silva VAO,
Vidal DO, Evangelista AF and Marques MMC: Overexpression of mir-183
and mir-494 promotes proliferation and migration in human breast
cancer cell lines. Oncol Lett. 14:1054–1060. 2017.PubMed/NCBI
|
|
36
|
Cheng C, Chen ZQ and Shi XT: MicroRNA-320
inhibits osteosarcoma cells proliferation by directly targeting
fatty acid synthase. Tumour Biol. 35:4177–4183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yan LX, Huang XF, Shao Q, Huang MY, Deng
L, Wu QL, Zeng YX and Shao JY: MicroRNA miR-21 overexpression in
human breast cancer is associated with advanced clinical stage,
lymph node metastasis and patient poor prognosis. RNA.
14:2348–2360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang B, Yang Z, Wang H, Cao Z, Zhao Y,
Gong C, Ma L, Wang X, Hu X and Chen S: MicroRNA-320a inhibits
proliferation and invasion of breast cancer cells by targeting
RAB11A. Am J Cancer Res. 5:2719–2729. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jin Y, Zhao M, Xie Q, Zhang H, Wang Q and
Ma Q: MicroRNA-338-3p functions as tumor suppressor in breast
cancer by targeting SOX4. Int J Oncol. 47:1594–1602. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu Y, Li Y, Liu J, Wu Y and Zhu Q:
MicroRNA-132 inhibits cell growth and metastasis in osteosarcoma
cell lines possibly by targeting Sox4. Int J Oncol. 47:1672–1684.
2015. View Article : Google Scholar : PubMed/NCBI
|
